Manufacturing-The-Impossible-Cell-&-Gene-Therapies-From-Bench-to-Billions

This panel at Danaher Summit 2026 gathers four cell and gene therapy manufacturing leaders — Amy Walker (Forbase Bio), Matthew Dy (Cell and Gene Therapy Catapult), Edwin Stone (Cellular Origins), and Manuel Corando (IBET) — to address the transition from bench-scale to commercial production. The discussion frames current manufacturing challenges against the historical precedent of penicillin's industrial scaling and connects them to the emerging 'bench to one' paradigm exemplified by Moderna's mRNA personalized cancer vaccine, which showed a 49% reduction in recurrence/death at ASCO 2026. Key themes include redefining the 'process is the product' axiom, bridging the analytical technology gap, and the future of continuous integrated bioprocessing for viral vectors.

Key Takeaways

Up to 31% of patients referred for CAR-T therapy never receive treatment because manufacturing queue times (2-7+ week vein-to-vein) allow disease to progress, making manufacturing failure a direct and measurable patient harm.
Moderna's mRNA personalized cancer vaccine — sequencing each tumor for up to 34 unique neoantigens and building a custom construct in six weeks — showed a 49% reduction in recurrence/death risk with pembrolizumab at ASCO June 2026, defining the 'bench to one' manufacturing frontier.
Matthew Dy reframes 'the process is the product' from a process-freeze excuse into a mandate: full process understanding enables continuous improvement and platform knowledge reuse across rare diseases sharing manufacturing platforms (lentiviral vectors, lipid nanoparticles).
Kite Pharma's Amsterdam CAR-T facility produces approximately 4 doses per operator per year (4,000 doses/year, ~1,000 headcount) — cited as proof that current autologous cell therapy manufacturing is not yet commercially viable and requires transformation of doses per square foot, doses per person, and cost of goods.
Edwin Stone argues for a capital-efficient scale strategy gated on clinical proof: the industry rewards clinical trial success but penalizes wrong manufacturing tool choices, a risk-culture mismatch that suppresses adoption of better technologies and must change.
Manuel Corando at IBET developed the first perfusion system for retroviruses (published 2002), addressing their 8-hour half-life at 37°C, and published continuous integrated gene therapy processes in 2010-2015; he identifies iPSC inputs, closed integrated continuous processing, and minimal total processing time as three near-future manufacturing imperatives.
Forbase Bio holds MHRA GMP certification for cell-free enzymatic DNA manufacturing — offering safety, speed, and cost advantages over entrenched plasmid DNA — but adoption is limited by familiarity; Walker identifies regulatory partnership and education of conservative pharma as the path to displacement.
Lentiviral vectors are re-emerging for in vivo CAR-T applications; IBET published (~2023) that tangential flow depth filtration overcomes the incompatibility of lentiviral clarification with standard TFF used for retroviruses.